Literature DB >> 35603011

Dysfunctional sarcomeric relaxation in the heart.

Walter E Knight1, Kathleen C Woulfe1.   

Abstract

Since cardiac relaxation is commonly impaired in heart failure caused by many different etiologies, identifying druggable targets is a common goal. While many factors contribute to cardiac relaxation, this review focuses on sarcomeric relaxation and dysfunction. Any alteration in how sarcomeric proteins interact can lead to significant shifts in sarcomeric relaxation that may contribute to diastolic dysfunction. Considering examples of sarcomeric dysfunction that have been reported in 3 different pathologies, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and heart failure with preserved ejection fraction, will provide insights into the role sarcomeric dysfunction plays in impaired cardiac relaxation. This will ultimately improve our understanding of sarcomeric physiology and uncover new therapeutic targets.

Entities:  

Keywords:  cardiac; cross-bridge cycling; heart failure with preserved ejection fraction; hypertrophic cardiomyopathy; relaxation; restrictive cardiomyopathy; sarcomere

Year:  2022        PMID: 35603011      PMCID: PMC9119547          DOI: 10.1016/j.cophys.2022.100535

Source DB:  PubMed          Journal:  Curr Opin Physiol        ISSN: 2468-8673


  57 in total

1.  Phenomapping for novel classification of heart failure with preserved ejection fraction.

Authors:  Sanjiv J Shah; Daniel H Katz; Senthil Selvaraj; Michael A Burke; Clyde W Yancy; Mihai Gheorghiade; Robert O Bonow; Chiang-Ching Huang; Rahul C Deo
Journal:  Circulation       Date:  2014-11-14       Impact factor: 29.690

2.  Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.

Authors:  Nazha Hamdani; Constantijn Franssen; André Lourenço; Inês Falcão-Pires; Dulce Fontoura; Sara Leite; Luisa Plettig; Begoña López; Coen A Ottenheijm; Peter Moritz Becher; Arantxa González; Carsten Tschöpe; Javier Díez; Wolfgang A Linke; Adelino F Leite-Moreira; Walter J Paulus
Journal:  Circ Heart Fail       Date:  2013-09-06       Impact factor: 8.790

Review 3.  Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Eli Muchtar; Lori A Blauwet; Morie A Gertz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

4.  The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils.

Authors:  Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Giulia D'Amati; Francesca Girolami; Magdi Yacoub; Franco Cecchi; Iacopo Olivotto; Corrado Poggesi
Journal:  J Physiol       Date:  2008-06-19       Impact factor: 5.182

Review 5.  Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility.

Authors:  Yuanhua Cheng; Michael Regnier
Journal:  Arch Biochem Biophys       Date:  2016-02-04       Impact factor: 4.013

6.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Christopher N Toepfer; Amanda C Garfinkel; Gabriela Venturini; Hiroko Wakimoto; Giuliana Repetti; Lorenzo Alamo; Arun Sharma; Radhika Agarwal; Jourdan F Ewoldt; Paige Cloonan; Justin Letendre; Mingyue Lun; Iacopo Olivotto; Steve Colan; Euan Ashley; Daniel Jacoby; Michelle Michels; Charles S Redwood; Hugh C Watkins; Sharlene M Day; James F Staples; Raúl Padrón; Anant Chopra; Carolyn Y Ho; Christopher S Chen; Alexandre C Pereira; Jonathan G Seidman; Christine E Seidman
Journal:  Circulation       Date:  2020-01-27       Impact factor: 29.690

7.  Cardiac Myosin Binding Protein-C Phosphorylation Mitigates Age-Related Cardiac Dysfunction: Hope for Better Aging?

Authors:  Paola C Rosas; Chad M Warren; Heidi A Creed; Jerome P Trzeciakowski; R John Solaro; Carl W Tong
Journal:  JACC Basic Transl Sci       Date:  2019-10-16

8.  Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy.

Authors:  Walter E Knight; Yingqiong Cao; Ying-Hsi Lin; Congwu Chi; Betty Bai; Genevieve C Sparagna; Yuanbiao Zhao; Yanmei Du; Pilar Londono; Julie A Reisz; Benjamin C Brown; Matthew R G Taylor; Amrut V Ambardekar; Joseph C Cleveland; Timothy A McKinsey; Mark Y Jeong; Lori A Walker; Kathleen C Woulfe; Angelo D'Alessandro; Kathryn C Chatfield; Hongyan Xu; Michael R Bristow; Peter M Buttrick; Kunhua Song
Journal:  Stem Cell Reports       Date:  2021-02-25       Impact factor: 7.765

9.  HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling.

Authors:  Joshua G Travers; Sara A Wennersten; Brisa Peña; Rushita A Bagchi; Harrison E Smith; Rachel A Hirsch; Lauren A Vanderlinden; Ying-Hsi Lin; Evgenia Dobrinskikh; Kimberly M Demos-Davies; Maria A Cavasin; Luisa Mestroni; Christian Steinkühler; Charles Y Lin; Steven R Houser; Kathleen C Woulfe; Maggie P Y Lam; Timothy A McKinsey
Journal:  Circulation       Date:  2021-03-08       Impact factor: 29.690

10.  Functionally Integrated Top-Down Proteomics for Standardized Assessment of Human Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissues.

Authors:  Jake A Melby; Willem J de Lange; Jianhua Zhang; David S Roberts; Stanford D Mitchell; Trisha Tucholski; Gina Kim; Andreas Kyrvasilis; Sean J McIlwain; Timothy J Kamp; J Carter Ralphe; Ying Ge
Journal:  J Proteome Res       Date:  2021-01-04       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.